|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
Biotechnology HealthcareInstructions for Authors of Feature ArticlesBiotechnology Healthcare reports on the how biopharmaceuticals and molecular diagnostics are managed and used, their value to third-party payers and employer purchasers, and how these audiences face the coverage, economic, and health policy issues biologics pose. We provide a forum for the discussion of these issues and how to overcome the challenges of providing appropriate access to biologics while keeping healthcare affordable. This publication is not, nor does it try to be, a scientific journal; rather, it is a guide to help decision makers understand what issues their peers are struggling with, how they are dealing with those issues, and how scientific advances shape trends and affect healthcare financing, utilization, and public policy. In producing the first publication dedicated to this purpose, it has been our hope that we will serve as a forum for thoughtful ideas and foster communication in an area where there is little consensus, some trial and error, a smattering of uninformed rationing, and a great deal of political grandstanding. Articles are written in accessible, conversational prose rather than the formal language of academic monographs (but see exception below), and on a level that is appropriate for a highly educated audience. Topics include economic, business, formulary, legal, policy, and big-picture issues; specialty pharmacy; diagnostics; outcomes management; ethical dilemmas; and pertinent legislation and regulation. We welcome articles by freelance business and medical writers within these broad subject areas. We also publish firsthand accounts of how third-party payers, employers and purchasing cooperatives, and healthcare professionals have met particular challenges. Most feature articles are commissioned, but we are eager for pitches from freelance writers and from bona fide experts. When considering articles by employees or representatives of profit-making concerns, we will reject pieces that promote a specific product. We have no way of validating product claims, nor do we make implicit endorsements. We prefer articles from such sources to be issue-oriented rather than self-promotional, offering readers genuine new and useful information. The advantage to the submitter is that such an article positions his or her company as a leader in the field. Feature articles by professional freelance writers in 2007 included:
Feature articles by physicians, benefit consultants, health plan administrators, and other professionals include:
Feature articles should range from 1,500 to 3,000 words. Manuscripts should be submitted electronically as Microsoft Word files. Send pitches electronically or by postal mail to: Katherine Adams Only original manuscripts that have not been published and are not under consideration by other publications will be considered. Authors should list any advanced academic degrees and provide a biography (1–2 sentences), including current job affiliation and relevant past experience. Writers on assignment for Biotechnology Healthcare are asked to follow the Biotechnology Healthcare stylebook. A copy can be found online at http://www.managedcaremag.com/MC-BH_Stylebook_1.0_Web.pdf. Peer-reviewed articlesBiotechnology Healthcare also publishes academic articles for peer review. We will consider impartial review articles by qualified experts and reports on original research. Topics can include (but are not limited to): the processes and procedures involved with integrating biotech agents and diagnostics into treatment plans; pharmacoeconomic analyses; the use of public databases and computational methods in meeting the challenges of healthcare delivery; policy and economic implications of emerging biotech applications in healthcare; and case studies. These articles are reviewed by members of the Biotechnology Healthcare editorial board. Authors will be requested to sign a disclosure form and transfer copyright to Biocommunications LLC. A complete description of the requirements for academic articles is available at: http://www.icmje.org. | |||||